Project title: MINIMAL INVASIVE SURGERY AND SAFE TREATMENT FOR FISTULA

Company name : RESQ MEDICAL LTD.

TECHNOLOGICAL FIELD
Medical devices

KEY WORDS
Minimal Invasive
Surgery, Fistula

PROJECT SUMMARY
A new minimal invasive and safe treatment for Fistula. Fistula is
a pathological tube that drains an internal abscess in the human
body through the skin surface. This tube is infected and
partially blocked by pus, fractured cells and gangrenous tissue.
The most common location for Fistula is in the rectal area.
With currently available methods, treatment for this problem is
aggressive surgery which requires general anesthesia and several
days of hospitalization. There is a high risk level of serious
complications, such as loss of control of the sphincter.

ResQ is developing a product that will treat many types of
Fistula, even very complicated cases, without the need for
general anesthesia and hospitalization. The device is intended
for single use and looks like a catheter, making it possible to
heal Fistula with a high rate of success, under local anesthesia
only and in a non-surgical environment. The suggested clinical
procedure is safe for the patient, and even in the event that the
procedure is not successful, it can be performed again, with
short patient recovery time. The device is made of silicone
rubber and produced via technologies that are common practice in
the medical world.

ENTREPRENEURS
Dr. Haim Halevy - Founder, CMO
Mr. Eran Herzowitz - Founder
Mr. Shaul Yemal - Management and Business
Development

In Cooperation with: Gali-Tech Ltd.

PROJECT STATUS
ResQ Medical was founded in July 2004.

The company now is in the process of obtaining a CE mark approval
for its first application product (expected in the second half of
2006), with FDA application and clearance planned for 2007. The
Israel Ministry of Health recently granted the device "AMR"
clearance, permitting the beginning of pre-marketing clinical
activity at the Tel Hashomer and Haemek Medical Centers. ResQ
Medical is advancing in the designing of a pilot study for the
treatment of Crohn's Disease Fistula.

Technology protected by USA patent granted and issued and PCT
patent pending application.
The estimated annual market for this technology, for first two
applications (Perianal fistula and Crohn's Disease fistulas) is
over USD 750 million, for the US, Western Europe and Japan.

COOPERATION REQUIRED
ResQ Medical is looking for marketing and sales agreement with
strategic partners.
------------------------------------------------
E-MAIL: shauly@resqmedical.com; halevy@resqmedical.com

Request for more information, about this project.

Note - you have to be registered in this server to request information. If you haven't done so yet, please:
Register in this server and your requests will be forwarded to the developer, who will contact you directly

List of projects that you already requested more information about